In 2022, Regeneron reported record revenue for EYLEA®, Dupixent® and Libtayo® and made exciting progress across the entire pipeline.
We’ve continued to expand the use of our commercial products with the FDA’s approval of Libtayo in combination with chemotherapy for non-small cell lung cancer, and the European Commission’s approval of Dupixent for prurigo nodularis. In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases and our promising oncology and hematology assets.
In January 2023, our Board of Directors authorized a $3.0 billion share repurchase program, enabling us to continue returning capital directly to shareholders. This year, we look forward to driving long-term shareholder value through continued investment in R&D, excellent commercial execution and strategic business development.
KEY 2022
FINANCIAL HIGHLIGHTS
$12.2B
Total revenue (w/ REGEN-COV)1
$11.5B Total revenue (w/o REGEN-COV)2
$3.6B
Total invested in R&D
$3.4B
Total allocated to business development and share repurchases
$8.7B
in global net product sales
(40% increase over 2021)3
$9.6B
in global net product sales
(4% increase over 2021)4
READ OUR SHAREHOLDER LETTER AND MORE IN OUR 2023 PROXY STATEMENT
PROXY STATEMENT2022 SELECT AWARDS AND RECOGNITIONS
Civic 50
Most Community Minded Companies in the Nation
Fortune
Best Workplaces in New York
IDEA Pharma
Pharmaceutical Innovation Index
Newsweek
America’s Most Responsible Companies
Prix Galien USA Award
Best Biotechnology Product for Inmazeb
S&P Global
Dow Jones Sustainability World Index
Science
Top Employer
Scrip Awards
Community Partnership of the Year
OUR CONTINUED REVENUE GROWTH
*2020: $8.5 billion total revenue (core business revenue: $8.3 billion2; REGEN-COV revenue: $186 million) 2021: $16.1 billion total revenue (core business revenue: $9.9 billion2; REGEN-COV revenue: $6.2 billion) 2022: $12.2 billion total revenue (core business revenue: $11.5 billion2; REGEN-COV revenue: $627 million)
1 Known as REGEN-COV in the United States and Ronapreve™ in other countries. Regeneron records net product sales of REGEN-COV in the United States and Roche records net product sales of Ronapreve outside the United States. The parties share gross profits from global sales of REGEN-COV and Ronapreve based on a pre-specified formula.
2 Revenue excluding REGEN-COV is a measure not calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP). Please see Table 3 of Regeneron’s fourth quarter and full year 2022 earnings release and fourth quarter and full year 2021 earnings release for a reconciliation of this measure to the most directly comparable U.S. GAAP financial measure.
3 Sanofi records global net product sales of Dupixent. Regeneron records its share of profits and losses in connection with global sales of Dupixent.
4 Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. Regeneron records its share of profits and losses in connection with sales of EYLEA outside the United States.